BioPharma Dive· Ben Fidler·· 5 hours agoScore39
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
In brief
At its R&D day, Arcus Biosciences presented follow-up data on casdatifan, its kidney cancer drug candidate. Analysts believe its efficacy may be superior to Merck's marketed drug Welireg, and the company's shares rose 8% that day.
Source: BioPharma Dive · biopharmadive.com